 |
 |
 |
Clay B. Siegall, Ph.D. President and Chief Executive Officer |
Clay Siegall co-founded Seattle Genetics in 1998 and
is the company’s President, Chief Executive Officer and
a member of the Board of Directors. Under his
leadership, Seattle Genetics has built a diverse
portfolio of clinical and preclinical antibody-based
therapies for the treatment of cancer and autoimmune
disease. The company has also developed proprietary
technologies for empowering antibodies, including its
industry-leading antibody-drug conjugate (ADC)
technology and its novel SEA technology. Dr. Siegall has
guided Seattle Genetics’ capital-raising activities,
securing more than $500 million through public and
private financings, including the company’s initial
public offering in 2001. In addition, the company has
entered into multiple strategic collaborations,
including with Millennium: The Takeda Oncology Company, Genentech (Roche), Bayer, MedImmune
(AstraZeneca), Agensys (Astellas) and Daiichi Sankyo.
Prior to co-founding Seattle Genetics, Dr. Siegall was
with the Bristol-Myers Squibb Pharmaceutical Research
Institute from 1991 to 1997 and the National Cancer
Institute, National Institutes of Health from 1988 to
1991. He serves on the Board of Directors of Alder
BioPharmaceuticals, a private biotechnology company, and
the Washington Biotechnology and Biomedical Association
(WBBA). Dr. Siegall is an author on more than 70
publications and holds 15 patents. He received a Ph.D.
in Genetics from George Washington University and a B.S.
in Zoology from the University of Maryland.
 |
Eric L. Dobmeier Chief Business Officer |
Eric Dobmeier joined Seattle Genetics in March 2002. He manages the company's business development, legal, corporate communications and project management groups. While at Seattle Genetics, he has led negotiation and completion of multiple corporate alliances, including the ex-U.S./Canada development and commercialization agreement with Millennium: The Takeda Oncology Company for brentuximab vedotin (SGN-35), the in-license of lintuzumab (SGN-33) from PDL BioPharma and ADC collaborations with Celldex Therapeutics, Progenics, Bayer, MedImmune, Daiichi Sankyo and Agensys. He has also participated in raising over $450 million in equity financing for Seattle Genetics. Prior to joining the company, Mr. Dobmeier was with the law firms of Venture Law Group and Heller Ehrman White & McAuliffe, where he represented technology companies in connection with public and private financings, mergers & acquisitions and corporate partnering transactions. Mr. Dobmeier holds a law degree from University of California, Berkeley and an undergraduate degree from Princeton University.
 |
Thomas C. Reynolds, M.D., Ph.D. Chief Medical Officer |
Tom Reynolds joined Seattle Genetics in March 2007. As Chief Medical Officer, he leads clinical and regulatory activities across the company's product portfolio. Dr. Reynolds has more than 15 years of biotechnology drug development experience, from preclinical development through the FDA approval process. Before joining Seattle Genetics, he was at Zymogenetics from 2002 to 2007, most recently as Vice President, Medical Affairs, where he oversaw the clinical development and BLA filing of rhThrombin and led the Medical Affairs department. Previously, he held various positions at Targeted Genetics including Vice President, Clinical Affairs, and before that was at Somatix Therapy (acquired by Cell Genesys in 1997). Dr. Reynolds holds a B.A. in Chemistry from Dartmouth College and both a Ph.D. in Biophysics and M.D. from Stanford University.
 |
Todd E. Simpson Chief Financial Officer |
Todd Simpson joined Seattle Genetics in October 2005, bringing extensive industry experience from senior financial positions with several public biotechnology companies. Prior to joining Seattle Genetics, he served as Vice President of Finance and Administration and Chief Financial Officer at Targeted Genetics since October 2001. Previously, he was Vice President, Finance and Administration and Chief Financial Officer of Aastrom Biosciences. From 1992 to 1996, he served in financial roles at Integra Life Sciences Corporation and Telios Pharmaceuticals, Inc. (which was acquired by Integra in 1995). Mr. Simpson practiced public accounting with the firm of Ernst & Young LLP from 1983 to 1992, primarily focused in the life sciences and technology practices. He is a certified public accountant and received his B.S. in accounting and computer science from Oregon State University.
 |
Vaughn B. Himes, Ph.D. Executive Vice President, Technical Operations |
Vaughn Himes joined Seattle Genetics in April 2009, bringing more than twenty years of experience in manufacturing, technical operations, process development and scale-up activities. As Executive Vice President, Technical Operations, he oversees Seattle Genetics' manufacturing, supply chain and quality assurance and control functions. Previously, Dr. Himes was with Zymogenetics, Inc., most recently as Senior Vice President, Technical Operations where his responsibilities included commercial and clinical manufacturing, supply chain and logistics, quality control and process development. While at Zymogenetics, he oversaw the chemistry, manufacturing and control (CMC) portion of the successful Biologics License Application for Recothrom™ and managed its commercial supply. Previously, he held Vice President positions in manufacturing and development at Corixa, Targeted Genetics and Genovo. Dr. Himes received a Bachelor of Arts in Chemistry from Pomona College in California and a Ph.D. in Chemical Engineering from the University of Minnesota.
 |
Morris Z. Rosenberg, D.Sc. Executive Vice President, Process Sciences |
Morris Rosenberg joined Seattle Genetics in July 2001 and was named Executive Vice President, Process Sciences in February 2009. Since joining the company, Dr. Rosenberg has overseen significant growth of the company's development organization, including the process development, quality assurance and control, analytical biochemistry, formulation and manufacturing functions. Prior to joining Seattle Genetics, he was with Eli Lilly from 1998 to 2001 where, as Head of Cell Culture and Fermentation Development, he led efforts in the development of several cell culture processes including for the sepsis therapeutic Xigris. Before that, he was at Biogen (now Biogen Idec) where he participated in development of the manufacturing process for Avonex, a multiple sclerosis treatment. Dr. Rosenberg received a D.Sc. in Chemical Engineering, an M.S. and B.S. in Chemical Engineering, and a B.A. in Biology from Washington University in St. Louis, Missouri.
 |
Bruce J. Seeley Executive Vice President, Commercial |
Bruce Seeley joined Seattle Genetics in October 2009 with more than 18 years of experience in oncology drug marketing and sales. As EVP, Commercial, Mr. Seeley will build and oversee Seattle Genetics’ marketing and sales functions as the company prepares for planned commercial operations. He previously worked at Genentech (a wholly owned member of the Roche Group), most recently as Senior Director for Herceptin (trastuzumab) and T-DM1 marketing. His responsibilities included development and implementation of marketing and launch strategies, including product differentiation, pricing, distribution, medical education and promotion. Before that, Mr. Seeley spent four years at Aventis Pharma in increasing roles of responsibility, including Head of New Product Commercialization and Licensing, Global Marketing, Oncology. While at Aventis, he managed the global marketing activities for Taxotere (docetaxel). Mr. Seeley also held various marketing and sales positions at Rhone-Poulenc Rorer and Bristol-Myers Squibb. He received a Bachelor of Arts in Sociology from the University of California at Los Angeles..
 |
Christopher Pawlowicz Senior Vice President, Human Resources |
Christopher Pawlowicz joined Seattle Genetics in September 2008. He has more than 25 years of human resources experience principally in the pharmaceutical industry. Prior to Seattle Genetics, Mr. Pawlowicz was Senior Vice President, Human Resources and Administration at MedPointe Pharmaceuticals, a private equity-backed specialty pharma company where he was part of the turnaround team that successfully restructured and sold the business to Meda Pharmaceuticals. Before that, he was Corporate Vice President, Human Resources at Express Scripts, the nation's third largest pharmacy benefit management company. Mr. Pawlowicz's career has also included senior human resources positions at Pharmacia, Searle and Monsanto. Highlights include the global launch of Celebrex, the start up of biotechnology commercial teams in plant sciences, support of high growth commercial investments in Latin America, Europe and Asia, and the post-merger integration of numerous companies. He graduated summa cum laude with a B.A. in Economics from Benedictine College, and received his M.A., Labor and Industrial Relations from the University of Illinois--Urbana-Champaign.
 |
Elaine Waller, PharmD Senior Vice President, Regulatory Affairs |
Elaine Waller, PharmD, joined Seattle Genetics in September 2008, bringing more than 20 years of experience in regulatory affairs and clinical research. Prior to joining Seattle Genetics, Dr. Waller was with Sonus Pharmaceuticals, where she served as Senior Vice President, Regulatory Affairs/Quality Assurance and Clinical Research until its merger with OncoGenex Pharmaceuticals in August 2008. Before that, she was Chief Operating Officer at Radiant Research, a clinical site management organization. Dr. Waller's previous experience includes senior positions in regulatory affairs and clinical research at Hoechst Marion Roussel and Marion Merrell Dow, predecessor companies to sanofi-aventis. She began her career in academia at the University of Texas at Austin where she held teaching positions in both graduate and undergraduate pharmacy education and was Assistant Director of Clinical Research at the Drug Dynamics Institute. Dr. Waller received a B.S. in Pharmacy and a Doctor of Pharmacy from the University of Missouri--Kansas City and an M.B.A. from Rockhurst College.
 |
Jonathan Drachman, M.D. Vice President, Translational Medicine |
Jonathan Drachman joined Seattle Genetics in November 2004. He oversees the activities involved in transitioning the company's antibody-based therapeutics from preclinical into clinical development, including clinical pharmacology, bioanalytical development and early-stage clinical trial execution. Prior to joining Seattle Genetics, Dr. Drachman was Associate Professor in the Hematology Division, Department of Medicine at the University of Washington in Seattle, where he remains a Clinical Associate Professor of Medicine. He also served as Senior Investigator in the Division of Research and Education and Medical Director of the Umbilical Cord Blood Program at the Puget Sound Blood Center. Dr. Drachman received a B.A. in biochemistry from Harvard University and an M.D. from Harvard Medical School. He completed his residency in Internal Medicine and fellowship in Medical Oncology at the University of Washington in Seattle.
 |
Kirk D. Schumacher Vice President, Legal Affairs & Compliance and General Counsel |
Kirk Schumacher joined Seattle Genetics in October 2003 and oversees all aspects of the company’s legal affairs and corporate compliance. Since joining Seattle Genetics, he has participated in the negotiation and completion of multiple corporate alliances, including the ex-U.S./Canada development and commercialization collaboration with Millennium: The Takeda Oncology Company for brentuximab vedotin (SGN-35), the in-license from PDL BioPharma of lintuzumab (SGN-33), as well as ADC technology collaborations with Celldex Therapeutics, Progenics, Bayer, MedImmune, Daiichi Sankyo, Millennium and Agensys. He has also participated in equity financings for Seattle Genetics, first as outside legal advisor and then as internal corporate counsel. Prior to joining the company, Mr. Schumacher was with the law firms of Venture Law Group and Riddell Williams, where he represented technology companies, including Seattle Genetics, in connection with public and private financings, SEC compliance and reporting, mergers and acquisitions and corporate partnering and licensing transactions. Mr. Schumacher received his J.D. from Columbia Law School and a B.A. from the University of Wisconsin.
 |
Peter D. Senter, Ph.D. Vice President, Chemistry and Distinguished Fellow |
Peter Senter joined Seattle Genetics in August 1998 and has served as Vice President, Chemistry since September 2002. In February 2009, Dr. Senter was recognized as the company's first Distinguished Fellow. He leads Seattle Genetics' chemistry department, which carries out research in antibody-drug conjugate technologies, including the development of potent drug payloads, novel linker systems, conjugation methodology and mechanism of action studies. Prior to joining the company, Dr. Senter was with Cytokine Networks, Inc., the Bristol-Myers Squibb Pharmaceutical Research Institute and the Dana-Farber Cancer Institute, Harvard Medical School. Dr. Senter received a Ph.D. in Chemistry from the University of Illinois, and an A.B. in Biochemistry from the University of California, Berkeley. He is the Senior Editor of Bioconjugate Chemistry and serves on the Editorial Board of four scientific journals. Dr. Senter is an Affiliate Professor of Bioengineering at the University of Washington. His research interests include targeted drug delivery, protein chemistry and biochemistry, and anti-cancer drug design. Dr. Senter has authored more than 100 scientific publications and holds more than 20 patents.
 |
Eric Sievers, M.D. Senior Medical Director |
Eric Sievers joined Seattle Genetics in July 2006. He is responsible for directing, planning and executing clinical development activities of several of the company's therapeutic programs, including brentuximab vedotin and lintuzumab. From 2003 to 2006, Dr. Sievers served as Medical Director at Zymogenetics supervising the oncology development of interleukin-21 and Atacicept. He performed his training in pediatric hematology and oncology at the University of Washington and the Fred Hutchinson Cancer Research Center, and served on the faculty of both institutions for over a decade. His academic research focused on improving treatment outcomes for patients with acute myeloid leukemia by defining the safety and efficacy of gemtuzumab ozogamicin (Mylotarg®) and evaluating novel flow cytometric techniques to predict leukemic recurrence. Dr. Sievers received both a B.A. in biology and an M.D. from Brown University. He is a member of the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research and the European Hematology Association, and is certified by the American Board of Pediatrics.